Publicaciones en colaboración con investigadores/as de Hospital Universitario de Valladolid (9)

2024

  1. Fibroblast growth factor 21 is a hepatokine involved in MASLD progression

    United European Gastroenterology Journal, Vol. 12, Núm. 8, pp. 1056-1068

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

2021

  1. Efficacy and safety of intramuscular administration of allogeneic adipose tissue derived and expanded mesenchymal stromal cells in diabetic patients with critical limb ischemia with no possibility of revascularization: study protocol for a randomized controlled double-blind phase II clinical trial (The NOMA Trial)

    Trials, Vol. 22, Núm. 1

  2. Mapping the human genetic architecture of COVID-19

    Nature, Vol. 600, Núm. 7889, pp. 472-477

2020

  1. Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus (Frontiers in Immunology, (2019), 10, 10.3389/fimmu.2019.01151)

    Frontiers in Immunology

2019

  1. Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus

    Frontiers in Immunology, Vol. 10, Núm. JUN

2018

  1. Home and ambulatory artificial nutrition (NADYA) report. home parenteral nutrition in Spain, 2017

    Nutricion Hospitalaria, Vol. 35, Núm. 6, pp. 1491-1496

2016

  1. Home Parenteral Nutrition in Spain, 2015. Home and Ambulatory Artificial Nutrition (NADYA) Group report

    Nutricion Hospitalaria, Vol. 33, Núm. 6, pp. 1487-1490